NVTA - Invitae Corporation

NYSE - NYSE Delayed Price. Currency in USD
14.09
-2.25 (-13.77%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close16.34
Open15.16
Bid14.12 x 1000
Ask14.13 x 1300
Day's Range14.00 - 15.93
52 Week Range7.41 - 28.75
Volume3,361,019
Avg. Volume3,520,540
Market Cap1.394B
Beta (5Y Monthly)2.03
PE Ratio (TTM)N/A
EPS (TTM)-2.66
Earnings DateFeb 18, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est31.08
  • Invitae and Muscular Dystrophy Association (MDA) Expand Access to No-Charge Genetic Testing in the U.S. and Canada
    PR Newswire

    Invitae and Muscular Dystrophy Association (MDA) Expand Access to No-Charge Genetic Testing in the U.S. and Canada

    Invitae (NYSE: NVTA), a leading medical genetics company today announced its partnership with the Muscular Dystrophy Association (MDA) to offer sponsored, no-charge genetic testing to patients through the Detect Muscular Dystrophy program in MDA's care center network, a network of clinics at more than 150 of the nation's top healthcare institutions.

  • Is the Options Market Predicting a Spike in Invitae (NVTA) Stock?
    Zacks

    Is the Options Market Predicting a Spike in Invitae (NVTA) Stock?

    Investors need to pay close attention to Invitae (NVTA) stock based on the movements in the options market lately.

  • Invitae Acquires Diploid, Maker of Artificial-Intelligence Engine to Enable Clinical Diagnosis Using Whole Genome Sequencing in Minutes
    PR Newswire

    Invitae Acquires Diploid, Maker of Artificial-Intelligence Engine to Enable Clinical Diagnosis Using Whole Genome Sequencing in Minutes

    Invitae Corporation (NYSE: NVTA), a leading medical genetics company, announced today the acquisition of Diploid, a privately held Belgian company that developed Moon, artificial intelligence (A.I.) software capable of diagnosing genetic disorders in minutes based on next-generation sequencing data and patient information.

  • Invitae to Acquire YouScript and Genelex to Make it Easier to Use Pharmacogenetic Information at the Point of Care
    PR Newswire

    Invitae to Acquire YouScript and Genelex to Make it Easier to Use Pharmacogenetic Information at the Point of Care

    Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced it has entered into definitive agreements to acquire YouScript, a privately held clinical decision support and analytics platform, and Genelex, a privately held pharmacogenetic testing company, to bring best-in-class pharmacogenetic testing, and robust, integrated clinical decision support to Invitae. Pharmacogenetic testing evaluates genetic variations that can impact how an individual responds to prescription medication.

  • Invitae to Present at Oppenheimer's 30th Annual Healthcare Conference
    PR Newswire

    Invitae to Present at Oppenheimer's 30th Annual Healthcare Conference

    Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that Sean George, co founder and chief executive officer of Invitae, will present at Oppenheimer's 30th Annual Healthcare Conference on Tuesday, March 17, 2020 at 1:00 p.m. Eastern in New York City.

  • Thomson Reuters StreetEvents

    Edited Transcript of NVTA earnings conference call or presentation 19-Feb-20 9:30pm GMT

    Q4 2019 Invitae Corp Earnings Call

  • Invitae to Present at the Cowen and Company's 40th Annual Health Care Conference
    PR Newswire

    Invitae to Present at the Cowen and Company's 40th Annual Health Care Conference

    Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the Cowen and Company's 40th Annual Health Care Conference on Monday, March 2, 2020 at 2:50 p.m. Eastern in Boston, Massachusetts.

  • Earnings Update: Here's Why Analysts Just Lifted Their Invitae Corporation Price Target To US$31.00
    Simply Wall St.

    Earnings Update: Here's Why Analysts Just Lifted Their Invitae Corporation Price Target To US$31.00

    It's been a sad week for Invitae Corporation (NYSE:NVTA), who've watched their investment drop 12% to US$23.82 in the...

  • Where the Bulls Roam: TSLA, ILMN, SQ, NVTA, TTD
    Zacks

    Where the Bulls Roam: TSLA, ILMN, SQ, NVTA, TTD

    Do you know which investment whales were buying and selling your favorite stocks before the big rally to new highs?

  • Invitae to Present at the 9th Annual SVB Leerink Global Healthcare Conference
    PR Newswire

    Invitae to Present at the 9th Annual SVB Leerink Global Healthcare Conference

    Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the 9th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 25, 2020 at 9:30 a.m. Eastern in New York City.

  • Invitae (NVTA) Reports Q4 Loss, Misses Revenue Estimates
    Zacks

    Invitae (NVTA) Reports Q4 Loss, Misses Revenue Estimates

    Invitae (NVTA) delivered earnings and revenue surprises of -5.00% and -3.63%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Invitae Reports $216.8 Million in Annual Revenue Driven by More Than 482,000 Samples in 2019
    PR Newswire

    Invitae Reports $216.8 Million in Annual Revenue Driven by More Than 482,000 Samples in 2019

    Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the fourth quarter and full year ended December 31, 2019.

  • Bull of the Day: Guardant Health (GH)
    Zacks

    Bull of the Day: Guardant Health (GH)

    Bull of the Day: Guardant Health (GH)

  • Cathie Wood, the Best Investor You’ve Never Heard Of
    Bloomberg

    Cathie Wood, the Best Investor You’ve Never Heard Of

    (Bloomberg Opinion) -- Who is Cathie Wood?She’s already in the pantheon of top money handlers over any period in the past five years, and has been the most persuasive — and so far prescient — champion of Tesla Inc.Her actively managed Ark Innovation ETF is the best performer among 584 funds with at least $1 billion of assets in the global equity market, crushing the likes of BlackRock with a return of 165% (income plus appreciation) the past three years, and she beat 99% of them since Ark Investment Management LLC became a registered investment adviser in January 2014, according to data compiled by Bloomberg.For all of her success picking winners, the 64-year-old Wood has received relatively little notice during the past three years, aside from being an occasional outlier among investors on CNBC. You won’t find her at the Barron’s Roundtable, which “gathers some of Wall Street’s best minds.” She was included in the Bloomberg 50: The People Who Defined Global Business in 2018. Her focus on innovation, “centered around genome sequencing, robotics, artificial intelligence, energy storage and blockchain technology,” enabled Ark Innovation ETF to increase 127 times, to $2.4 billion from its $15 million grubstake in 2017. In the process, the Ark ETF rewarded its shareholders with more than three times the return of the S&P 500 Index and more than twice the Nasdaq’s bounty. Since its inception, Ark has earned almost 2.4 times more than the S&P 500 and 1.7 times the Nasdaq, according to data compiled by Bloomberg.At a point when money management mostly is a passive, index-driven business, Wood is a discerning stock picker with about $11 billion of assets. Her selection of health-care juggernauts Juno Therapeutics Inc., based in Seattle, and Invitae Corp., in San Francisco, returned 286% and 173%, respectively, in the past three years. Choosing Palo Alto-based Tesla and Buenos Aires-based MercadoLibre Inc. among consumer discretionary companies netted 185% and 269% in her fund, according to data compiled by Bloomberg.“We’re all about finding the next big thing,” said Wood during an initial interview with David Westin on Bloomberg Wall Street Week earlier this month. “Anyone hewing to the benchmarks, which are backwards looking, they’re not about the future. They are about what has worked. We’re all about what is going to work.”Since she graduated summa cum laude in finance and economics from the University of Southern California in 1981, Wood has been assistant economist at the Capital Group; chief economist, analyst, portfolio manager and director at Jennison Associates; co-founder of the hedge fund Tupelo Capital Management, and chief investment officer of global thematic strategies at AllianceBernstein, where she managed more than $5 billion. Her favorite innovator is Copernicus, the Renaissance man who located the sun rather than the Earth at the center of the universe.Soon after launching Ark in 2014, Wood made Tesla her fifth-largest holding. In 2018, she increased it to No. 1, or 10% of the fund, as most analysts soured on the maker of zero-emission, battery-electric vehicles.In 2016, when Tesla plummeted 11%, and 75% of the analyst recommendations opposed any purchases, Wood almost tripled her Tesla position to 5,072 shares. The following year, after Tesla appreciated 46%, and 68% of the analysts remained bearish, she enlarged her stake more than 13 times to 67,653 shares, according to data compiled by Bloomberg. When Tesla rallied 26% last year amid tepid recommendations from 70% of the analysts, she almost doubled her stake to 471,594 shares.Tesla continued climbing this year — 91%, the best performer in the Nasdaq 100 index and No. 1 among the 500 most highly capitalized U.S. companies. Wood was a consistent seller during the rally — reducing her holding to 292,000 shares — solely to keep her Tesla stake at the designated maximum 10% of her fund.“If we hadn’t sold, Tesla would probably be well north of 20% in the portfolio,” she said during a phone interview last week. “Last year, we were buying aggressively when analysts were saying Tesla was going to run out of cash and go bankrupt.” Tesla still is “incredibly undervalued,” she said.That’s an opinion considered absurd by most analysts, who insist nothing justifies Tesla’s valuation at almost $150 billion, or 58% more than the market capitalization of global sales leader Volkswagen AG.On the contrary, says Wood, Tesla’s share of EV sales increased a percentage point to 18% when the so-called Tesla killers — from BYD Co. Ltd and BAIC Motor Corp. in China to Nissan Motor Co. in Japan and Volkswagen, Bayerische Motoren Werke AG and Daimler AG in Germany and General Motors Co. and Ford Motor Co. in the U.S — started selling their own battery-electric vehicles. Wood believes the legacy automakers will lose money on their EVs, while Tesla becomes increasingly profitable and remains years ahead of its rivals in battery and chip technology.The company also has 14 billion miles of real-world driving data. Its closest competitor, Waymo, has data on 20 million miles.The investors who have been Tesla naysayers have gotten far more attention than Wood. News articles about Tesla short sellers, including David Einhorn’s Greenlight Capital LLC and Jim Chanos of Kynikos Associates Ltd., are far more numerous on the Bloomberg system. More than 100 stories showcased Einhorn’s disdain for Tesla, and more than 40 similarly featured Chanos, while there were around 20 for Wood during the same period.Investors were similarly dubious about Amazon.com, which appreciated 1,029% during its first five years after the initial public offering in 1997 and 228% during its second five-year period. Tesla has gained 1,018% during the five years after its 2010 IPO and appreciated 206% since 2015, according to data compiled by Bloomberg. “It’s the same idea that analysts hated Amazon during that entire period – not on the bubble but after the tech and telecom bust,” Wood said.In her latest assessment last month, she wrote: “Based on our updated expectations for electric vehicle (EV) cost declines and demand, as well as our estimates for the potential profitability of robotaxis, our 2024 expected value per share for TSLA is $7,000.”That’s a far cry from the $340 in August 2018, when Chief Executive Officer Elon Musk tweeted: “Am considering taking Tesla private at $420. Funding secured.”Musk subsequently received a letter from Wood urging him not to take the company private because she saw Tesla rallying to $4,000 in five years. Before the month ended, he said his plan to take Tesla private wasn’t “the better path.” Even Musk seemed impressed by Wood’s judgment. “The letter was to him and the board, and he did say that he and the board took the letter into consideration and it did influence them,” she said.Tesla said last week that it will sell about $2 billion of new shares and that Musk would purchase as much as $10 million of the offering.“I’m not going to tell you we were the reason,” Wood said. “We were a little peapod back then, and we’re still a little peapod in the scheme of the asset management world.” But, she said, “I think our research is the best in the world on Tesla.”So far at least, she’s been right on the money.\-- With assistance from Shin PeiTo contact the author of this story: Matthew A. Winkler at mwinkler@bloomberg.netTo contact the editor responsible for this story: Katy Roberts at kroberts29@bloomberg.netThis column does not necessarily reflect the opinion of Bloomberg LP and its owners.Matthew A. Winkler is Co-founder of Bloomberg News (1990) and Editor-in-Chief Emeritus; Bloomberg Opinion Columnist since 2015; Co-founder of Bloomberg Business Journalism Diversity Program in 2017. During his 25 years as Editor-in-Chief, Bloomberg News was a three-time finalist and winner of the Pulitzer Prize for Explanatory Reporting and received numerous George Polk, Gerald Loeb, Overseas Press Club and Society of Professional Journalists and Editors (Sabew) awards.For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • Invitae (NVTA) Gains As Market Dips: What You Should Know
    Zacks

    Invitae (NVTA) Gains As Market Dips: What You Should Know

    Invitae (NVTA) closed at $26.25 in the latest trading session, marking a +1.86% move from the prior day.

  • Invitae (NVTA) Expected to Beat Earnings Estimates: Should You Buy?
    Zacks

    Invitae (NVTA) Expected to Beat Earnings Estimates: Should You Buy?

    Invitae (NVTA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Drug makers tap genetic test to save kids with seizures
    American City Business Journals

    Drug makers tap genetic test to save kids with seizures

    As more drug companies subsidize the cost of the genetic test, more patients can be tested and, potentially, matched to the companies' drugs.

  • Invitae to announce fourth quarter and full year 2019 financial results on February 19, 2020
    PR Newswire

    Invitae to announce fourth quarter and full year 2019 financial results on February 19, 2020

    Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its fourth quarter and full year 2019 financial results on Wednesday, February 19, 2020 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights.

  • Implied Volatility Surging for Invitae (NVTA) Stock Options
    Zacks

    Implied Volatility Surging for Invitae (NVTA) Stock Options

    Investors need to pay close attention to Invitae (NVTA) stock based on the movements in the options market lately.

  • 5 Top Stock Trades for Tuesday: CGC, T, ROKU
    InvestorPlace

    5 Top Stock Trades for Tuesday: CGC, T, ROKU

    With no reason to sell off, why wouldn't stocks continue higher on Monday? Let's look at a few top stock trades for Tuesday, when earnings season will begin with the banks. Top Stock Trades for Tomorrow No. 1: Canopy Growth (CGC)Source: Chart courtesy of StockCharts.comThe cannabis space is far from being out of the woods, but there are two names in the group that I have liked recently, one of which is Canopy Growth (NYSE:CGC).Canopy shares are hitting their highest level since October, as shares push higher on Monday. In doing so, CGC is reclaiming both the $22 level and the 100-day moving average.InvestorPlace - Stock Market News, Stock Advice & Trading TipsIt might get there in a few days or it might take a few months, but a rally up and over $25 into the upper-$20s shouldn't be out of the question now. * 7 Inflation-Beating REITs to Ground Your Income Portfolio On the downside, it would be best for CGC to hold $21.50 as support. Below that level and bulls will need to see the 50-day and uptrend support (purple line) need to hold as support. Top Stock Trades for Tomorrow No. 2: AT&T (T)Source: Chart courtesy of StockCharts.comResistance continues to hold near $39 for AT&T (NYSE:T), while Monday's pullback is sending T stock right into the 50-day moving average and uptrend support (blue line). This one is simple now.Below uptrend support and the 100-day moving average is in play. Below that and the $36 to $36.50 area is possible. If current support holds, look for a rebound back up to $39. If it can get over that level, AT&T could be looking at $40-plus. Top Stock Trades for Tomorrow No. 3: Roku (ROKU)Source: Chart courtesy of StockCharts.comWhile many growth stocks have been rallying, Roku (NASDAQ:ROKU) has been struggling. Shares did reverse off $127 support on Monday, but still face downtrend resistance (blue line) overhead.Falling below the 20-day and 50-day moving averages does not bode well for momentum, but Roku isn't completely stuck.A move back over downtrend resistance and the 50-day moving average could trigger a rally up to $150-plus. However, a move below $127 puts the $117 to $120 area on watch, with the 200-day moving average just below. Top Stock Trades for Tomorrow No. 4: Aphria (APHA)Source: Chart courtesy of StockCharts.comAt the top, I mentioned that I liked two cannabis stocks. CGC was the first and Aphria (NYSE:APHA) is the other. The latter isn't moving quite as nicely as the former, but it's showing breakout potential.Rallying into the 100-day moving average and downtrend resistance (blue line) now, APHA stock has a chance to power higher and draw in buyers.A move over $5.50 would add to its momentum and put the declining 200-day moving average in play. If it can't hurdle current resistance, see that it holds up over the 50-day moving average. Below that level puts $4.50 back on the table. Top Stock Trades for Tomorrow No. 5: Invitae (NVTA)Source: Chart courtesy of StockCharts.comWhat a wild ride it has been with Invitae (NASDAQ:NVTA). Shares are surging higher on Monday after an update from management on Sunday night regarding 2019 results and 2020 guidance.The news sent shares higher by about 10%, with many longs wondering if this is the start of something big or if it will ultimately deflate like the last pop.The stock is back over $17, while uptrend support (blue line) continues to hold. Shares are clearing downtrend resistance (purple line), and while investors will be looking at $20, that's not the level to watch. Instead, it's the 50-week moving average at $20.55.Over that level and NVTA can really start to find its momentum.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long ROKU, T, APHA and NVTA. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Inflation-Beating REITs to Ground Your Income Portfolio * 7 Healthcare Stocks to Buy or Sell As Pricing Pressures Mount * 7 Earnings Reports to Watch This Week The post 5 Top Stock Trades for Tuesday: CGC, T, ROKU appeared first on InvestorPlace.

  • How a Union Square dentist office bridges to biotech during JPM Week
    American City Business Journals

    How a Union Square dentist office bridges to biotech during JPM Week

    When meeting space is at a premium during the week of biotech's big dealmaking conference, a Union Square tenant creatively bonds with a San Francisco company.

  • Invitae preliminary 2019 financial results demonstrate strong momentum with nearly 60% growth in test volume and more than 45% growth in revenue year-over-year
    PR Newswire

    Invitae preliminary 2019 financial results demonstrate strong momentum with nearly 60% growth in test volume and more than 45% growth in revenue year-over-year

    Invitae Corporation (NYSE: NVTA), a leading medical genetics company, announced preliminary unaudited full-year 2019 results, driving strong growth in volume and revenues, signaling continued momentum going into 2020. The company accessioned more than 482,000 samples and generated approximately $216 million in revenue in 2019. The company also announced 2020 guidance of more than 725,000 samples accessioned and more than $330 million in revenue, reflecting a more than 50% annual growth in both volume and revenue. Invitae has now provided in-depth medical genetic sequencing for more than one million patients since launch, including more than 750,000 in the past two years.

  • Biotechs punch up talking points leading into big Union Square conference
    American City Business Journals

    Biotechs punch up talking points leading into big Union Square conference

    Life sciences companies like to release a flurry of news in the days ahead of the giant J.P. Morgan Healthcare Conference in San Francisco to create fresh nuggets for potential investors and partners to gnaw on. Yet too much noise sometimes can hurt their message.

  • Behind the Seizure® Program Further Expands Access to Genetic Testing for Children to Speed the Diagnosis of Genetic Epilepsy
    PR Newswire

    Behind the Seizure® Program Further Expands Access to Genetic Testing for Children to Speed the Diagnosis of Genetic Epilepsy

    Today BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and Invitae Corporation (NYSE: NVTA) announced that Biogen (NASDAQ: BIIB), Encoded Therapeutics, Neurogene, Praxis Precision Medicines and PTC Therapeutics joined Behind the Seizure®, an innovative, cross-company collaboration that aims to provide faster diagnosis for young children with epilepsy. The program will also be expanded to make no-charge testing available for healthcare providers to order for any child under the age of eight who has an unprovoked seizure.